Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the IUPAC name (2E)-2-{[(2S)-2-carboxy-2-(phenoxyacetamido)ethoxy]imino}pentanedioic acid. It has been studied as an experimental inhibitor of penicillin-binding proteins (PBPs), which are essential enzymes involved in bacterial cell wall synthesis. The compound is structurally related to lactivicins, a class of non-beta-lactam antibiotics that mimic the D-Ala-D-Ala terminus of peptidoglycan precursors and inhibit PBPs by covalent binding to their active site serine residues. This mechanism disrupts cell wall biosynthesis, leading to antibacterial effects[7][1][2]. Its primary research context has been structural and mechanistic studies rather than clinical development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (2E)-2-({(2S)-2-carboxy-2-[(phenoxyacetyl)amino]ethoxy}imino)pentanedioic acid.